UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): October 03, 2022 |
Hyperfine, Inc.
(Exact name of Registrant as Specified in Its Charter)
Delaware |
001-39949 |
98-1569027 |
||
(State or Other Jurisdiction |
(Commission File Number) |
(IRS Employer |
||
|
|
|
|
|
351 New Whitfield Street |
|
|||
Guilford, Connecticut |
|
06437 |
||
(Address of Principal Executive Offices) |
|
(Zip Code) |
Registrant’s Telephone Number, Including Area Code: (866) 796-6767 |
N/A |
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
|
|
Trading |
|
|
Class A common stock, $0.0001 par value per share |
|
HYPR |
|
The NASDAQ Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
President and Chief Executive Officer Appointment
On October 6, 2022, Hyperfine, Inc. (the “Company”) announced that Maria Sainz, one of the Company’s current directors, was appointed by the Board of Directors of the Company (the “Board”) as President and Chief Executive Officer of the Company, effective as of October 24, 2022 (the “Appointment Date”). Ms. Sainz will also continue to serve as a director on the Board. In connection with Ms. Sainz’s appointment, R. Scott Huennekens, who has been serving as Interim President and Chief Executive Officer of the Company, will step down from that role effective as of the Appointment Date. Mr. Huennekens will continue to serve as Executive Chairperson of the Board.
Ms. Sainz, age 56, has served on the Board since the closing of the Company’s business combination in December 2021. Ms. Sainz also serves as member of the board of directors of ShockWave Medical, Inc., Avanos Medical, Inc. and Atrion Corporation, and was previously on the board of Orthofix Medical Inc., Iridex Corporation and MRI Interventions, Inc. Ms. Sainz served as the President and Chief Executive Officer of AEGEA Medical, a medical device company in the women’s health space focused on the development of technology for endometrial ablation, from May 2018 through February 2021. Prior to that, she served as the President and Chief Executive Officer of Cardiokinetix, a medical device company, from 2012 until 2017. Ms. Sainz received a Bachelor of Arts in Linguistics from the University Complutense in Madrid, Spain and a Masters in International Business from the American Graduate School of International Management. Ms. Sainz’s qualifications to serve on the Board include her leadership experience in the healthcare industry.
The selection of Ms. Sainz to perform the functions of President and Chief Executive Officer was not pursuant to any arrangement or understanding between Ms. Sainz and any other person. There are no family relationships between Ms. Sainz and any director or executive officer of the Company, and there are no transactions between Ms. Sainz and the Company that would be required to be reported under Item 404(a) of Regulation S-K.
On October 4, 2022, the Company entered into an offer letter of employment with Ms. Sainz, effective as of the Appointment Date (the “Offer Letter”). Pursuant to the terms of the Offer Letter, Ms. Sainz’s annual base salary is $550,000. Ms. Sainz is eligible to receive an annual discretionary bonus with a target of 90% of her base salary. Ms. Sainz will receive a one-time sign-on bonus in the amount of $125,000, which is recoverable in full by the Company in the event that Ms. Sainz voluntarily terminates her employment with the Company or is terminated for “cause” (as defined in the Hyperfine, Inc. Executive Severance Plan, as amended (the “Severance Plan”)) prior to the 12 month anniversary of the Appointment Date. The Offer Letter further provides that Ms. Sainz will receive an award of stock options to purchase 3,175,000 shares of Class A common stock of the Company as of the effective date of the stock option repricing previously approved by the Board on August 24, 2022, which is expected to be on or about October 31, 2022, with 25% of the stock options to vest on the last day of the calendar month that includes the one year anniversary of the Appointment Date, and 2.08% at the end of each month thereafter, subject to Ms. Sainz’s continued service to the Company through the applicable vesting dates. Commencing on the Appointment Date, Ms. Sainz will become a participant in the Company’s Severance Plan. The foregoing description of the Offer Letter is not complete and is qualified in its entirety by reference to the full text of the Offer Letter, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K.
Further, in connection with Ms. Sainz’s membership on the Board, Ms. Sainz and the Company previously entered into an indemnification agreement in the form the Company has entered into with its other executive officers and directors, which form is filed as Exhibit 10.24 to the Company’s Current Report on Form 8-K, filed with the U.S. Securities and Exchange Commission on December 28, 2021.
Amended Executive Severance Plan
On October 3, 2022, the Board amended the Severance Plan to include the Chief Executive Officer as a participant in the Severance Plan effective October 1, 2022, but the terms of the Severance Plan did not otherwise change. Participants in the Severance Plan include the Chief Executive Officer and all employees with the title of Vice President, including Executive Vice President, Senior Vice President and Vice President.
Under the Severance Plan, if the Company terminates a participant’s employment without cause (as defined in the Severance Plan) at any time other than during the twelve (12) month period following a change in control (as such term is defined in the Severance Plan) (the “Change in Control Period”), then the participant is eligible to receive the following benefits:
|
|
|
Severance payable in the form of salary continuation or a lump sum payment. The severance amount is equal to participant’s then-current base salary times a multiplier determined based on the participant’s title or role with us. |
|
|
|
The Company will pay for company contribution for continuation coverage under the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (“COBRA”) during the severance period. |
Under the Severance Plan, if the Company terminates a participant’s employment without cause or a participant resigns for good reason, during the Change in Control Period, then the participant is eligible to receive the following benefits:
|
|
|
Severance payable in a single lump sum. The severance amount is equal to participant’s then-current base salary and then-current target annual bonus opportunity, times a change in control multiplier determined based on the participant’s title or role with us. |
|
|
|
The Company will pay for company contribution for continuation coverage under COBRA during the severance period. |
|
|
|
Any outstanding unvested equity awards held by the participant under any then-current outstanding equity incentive plan(s) will become fully vested as of the date the termination of such participant’s employment becomes effective. |
A participant’s rights to any severance benefits under the Severance Plan are conditioned upon the participant executing and not revoking a valid separation and general release of claims agreement in a form provided by the Company.
The foregoing description of the Severance Plan is not complete and is qualified in its entirety by reference to the full text of the Severance Plan, a copy of which is filed as Exhibit 10.2 to this Current Report on Form 8-K.
Executive Chairperson Compensation
On October 4, 2022, the Board approved the terms of compensation to be granted to Mr. Huennekens for his service as Executive Chairperson of the Board. Mr. Huennekens will be compensated in the amount of $10,000 per month, effective as of the Appointment Date, and continuing until his successor has been appointed or until his earlier death, resignation or removal. In addition, Mr. Huennekens will continue to be entitled to an annual cash retainer fee of $50,000, an annual equity grant and the reimbursement of expenses for his service as a non-employee director in accordance with the Company’s Nonemployee Director Compensation Policy.
Item 7.01. Regulation FD Disclosure.
On October 6, 2022, the Company issued a press release announcing the appointment of Ms. Sainz, as described in Item 5.02 above. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.
The information in Item 7.01 of this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
Exhibit Number |
|
Description |
10.1+ |
|
Offer Letter, dated as of October 4, 2022, by and between Hyperfine, Inc. and Maria Sainz |
10.2+ |
|
|
99.1 |
|
|
104 |
|
Cover Page Interactive Data File (embedded within the Inline XBRL document) |
+ Management contract or compensatory plan or arrangement.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
HYPERFINE, INC. |
|
|
|
|
Date: |
October 6, 2022 |
By: |
/s/ Neela Paykel |
|
|
|
Neela Paykel |
Exhibit 10.1
Hyperfine, Inc.
October 4, 2022
Maria Sainz
Dear Maria:
On behalf of Hyperfine, Inc., I am pleased to offer you the position as President and Chief Executive Officer beginning on October 24, 2022 (your “Start Date”). You will report to the Executive Chairperson of the Hyperfine Board of Directors. Your annualized compensation in this position will consist of an annual base salary of $550,000 paid in biweekly pay periods, less required deductions.
Beginning with the 2022 calendar year, you will be considered for an annual discretionary bonus targeted at 90% of your annual base salary, which bonus, if any, will be prorated for the 2022 calendar year based on your Start Date and the terms of the Hyperfine employee bonus plan. Beginning with respect to the annual discretionary bonus for the 2023 calendar year, at the end of each previous calendar year, the Board of Directors will establish performance goals and targets for the applicable year. Any awarded bonus shall be paid no later than March 15 of the following calendar year, and it will be a condition of your eligibility to receive any bonus that you remain employed with Hyperfine through the scheduled date of payment of such bonuses.
You will receive a one-time taxable sign on bonus of $125,000. One half of that amount will be paid to you in the first available payroll date after your Start Date. The second half of the amount will be paid to you 6 months following your Start Date in the next available payroll date. Such payments will be recoverable in full by the company in the event you voluntarily terminate your employment or are terminated for “cause” (as defined in the Hyperfine, Inc. Executive Severance Plan) prior to 12 months from your Start Date.
In addition to the outlined cash compensation, you will receive 3,175,000 stock options in Hyperfine that (i) will be subject to the approval of Hyperfine’s Board of Directors, (ii) will be subject to the terms of the grant documents therefore, (iii) subject to continued service and the specific terms of your grant, will vest over a four year period with the following schedule: 25% on the last day of the calendar month that includes the one year anniversary of your Start Date, and 2.08% at the end of each month thereafter. You will also be eligible for, but not guaranteed to receive, an annual time-based equity award in March 2024.
You will be eligible for participation in the Hyperfine, Inc. Executive Severance Plan, and you will become a participant in such Executive Severance Plan commencing on your Start Date.
You will continue as a member of the Board of Directors following your Start Date. In the event your employment with the Company terminates for any reason, you will resign from the Board of Directors as of your termination date.
You will devote your best efforts and substantially all of your business time to the performance of your duties as Chief Executive Officer. Notwithstanding the foregoing, subject to the advance approval of the Board of Directors, which approval will not be unreasonably withheld, you will
be entitled to serve on boards of directors, professional, civic, charitable, educational, religious, public interest, public service or medical advisory boards, in each case to the extent such activities do not materially interfere, as determined by the Board of Directors in good faith, with the performance of your duties and responsibilities hereunder.
You will be based out of Hyperfine’s California facility, with the expectation that you will travel regularly, as appropriate and as requested by the Executive Chair or the Board, to the Company’s offices in Connecticut.
You will also be eligible to participate in medical and other benefit plans in accordance with the rules and eligibility of those plans currently in effect. Health insurance shall commence on November 1, 2022. Further, while we expect you to remain with Hyperfine for a long time, this letter is not an employment contract and you will be an at-will employee.
Hyperfine considers the protection of its confidential information, proprietary materials and goodwill to be extremely important. As a condition of this offer of employment, you are required to sign Hyperfine’s Non-solicit, Confidentiality and Intellectual Property Agreement, and other policies contained in the Company’s Employee Handbook.
We appreciate your exceptional talent and are very excited about you joining our growing and dynamic team at Hyperfine. We firmly believe that Hyperfine offers a unique combination of emotional, intellectual, and interpersonal stimulation that will be truly enjoyable. As a member of our growing team, you will be in the rare position of helping to shape the culture and direction of our organization. We have tremendous opportunities ahead of us, and I am confident you have the expertise required to help us achieve our objectives. If you have any questions regarding this offer, the position, or the company’s benefits programs, please do not hesitate to reach out.
Please note that this offer will expire on October 7, 2022, unless accepted by you in writing prior to such date.
Sincerely,
Hyperfine, Inc.
By: /s/ R. Scott Huennekens
R. Scott Huennekens
Executive Chairperson of the Board
ACCEPTED AND AGREED:
By: /s/ Maria Sainz
Maria Sainz
Date: 10/04/2022
Exhibit 10.2
HYPERFINE EXECUTIVE SEVERANCE PLAN
PLAN DOCUMENT AND SUMMARY PLAN DESCRIPTION
Effective as of October 1, 2022
2
3
4
5
6
7
Hyperfine, Inc.
351 New Whitfield Street
Guilford, CT 06437
Attention: Chief People Officer
administrator@hyperfine.io
8
Plan Administrator
Hyperfine, Inc.
351 New Whitfield Street
Guilford, CT 06437
9
Plan Administrator
Hyperfine, Inc.
351 New Whitfield Street
Guilford, CT 06437
A request for review must set forth all of the grounds on which it is based, all facts in support of the request and any other matters that the applicant feels are pertinent. The Plan Administrator may require the applicant to submit additional facts, documents or other material as he or she may find necessary or appropriate in making his or her review.
10
11
12
Hyperfine, Inc.
351 New Whitfield Street
Guilford, CT 06437
Attention: Chief People Officer
administrator@hyperfine.io
Hyperfine, Inc.
351 New Whitfield Street
Guilford, CT 06437
Attention: Chief People Officer
With a copy to:
Hyperfine, Inc.
351 New Whitfield Street
Guilford, CT 06437
Attention: legal@hyperfine.io
13
EXHIBIT A
MULTIPLIERS
Job Level |
Normal Multiplier |
CIC Multiplier |
Chief Executive Officer |
1.5 |
1.5 |
EV-3 |
1.0 |
1.0 |
EV-2 |
0.75 |
0.75 |
EV-1 |
0.5 |
0.5 |
IF " DOCVARIABLE "SWDocIDLocation" 3" = "3" " DOCPROPERTY "SWDocID" 116231672v.4" "" 116231672v.4
14
Exhibit 99.1
Hyperfine Names Maria Sainz President and Chief Executive Officer
GUILFORD, Connecticut, October 6, 2022 (GLOBE NEWSWIRE) – Hyperfine, Inc. (Nasdaq: HYPR), (“Hyperfine” or “the Company”), the groundbreaking medical device company that created Swoop®, the world's first FDA-cleared portable MRI system, today announced that it has named medical device industry veteran Maria Sainz as President and Chief Executive Officer (CEO) of Hyperfine, effective October 24, 2022. Scott Huennekens, who currently serves as interim President and CEO, will stay on as Executive Chairperson of the Board.
Ms. Sainz has held President and CEO positions at multiple medical device companies in her industry tenure, including AEGEA Medical, acquired by CooperSurgical in 2021, Cardiokinetix, and Concentric Medical, acquired by Stryker in 2011. She brings over 30 years of experience in the medical device industry and has served as a valuable member of Hyperfine’s Board of Directors since the company’s Nasdaq listing, including on both the Audit Committee and Nominating and Corporate Governance Committee. As President and CEO of Hyperfine, Ms. Sainz will lead the commercial expansion of Hyperfine’s Swoop portable MRI system to execute the company’s mission of lowering barriers to medical imaging around the world.
“I am excited and honored to lead the next phase of Hyperfine’s growth as we broaden the adoption of Swoop technology, improving access to MR imaging around the world,” said Ms. Sainz. “With over 90 systems installed globally and our growing value proposition in the ICU and neurocritical care settings, we have established a strong foundation to drive forward commercial momentum. I am eager to join the Hyperfine team as we expand to additional hospitals and continue increasing our clinical applications to improve patient care in mature and emerging healthcare systems.”
“We are very pleased to name Ms. Sainz President and CEO of Hyperfine. She carries a successful track record of execution and shareholder value creation across medical device businesses, and her decades of experience are immensely valuable,” said Scott Huennekens, Executive Chairperson of the Hyperfine Board of Directors. “I am confident in her ability to manage the business with a disciplined approach to spending while leading Hyperfine into its next phase of growth by expanding the Swoop commercial footprint to new sites of care.”
“Ms. Sainz has the experience, judgement, and speed needed to ensure that Hyperfine continues to define and own the field of portable MRI. Since inception, Hyperfine has been a technical and AI powerhouse, and now Hyperfine needs to be a commercial force. Ms. Sainz brings the experience, intelligence, and capability to the table to execute that plan,” said Dr. Jonathan Rothberg, Hyperfine’s Founder and Vice Chairman.
About Hyperfine
Hyperfine, Inc. is the groundbreaking medical device company that created Swoop®, the world’s first FDA-cleared portable MRI system. Hyperfine designed Swoop to enable rapid diagnoses and treatment for every patient regardless of income, resources, or location, pushing the boundaries of conventional imaging technology and expanding patient access to life-saving care. The Swoop Portable MR Imaging System produces high-quality images at a lower magnetic field strength, allowing clinicians to quickly scan, diagnose, and treat patients in various clinical settings. Swoop can be wheeled directly to the patient’s bedside, plugged into a standard electrical wall outlet, and controlled by an iPad®. Designed as a complementary system to conventional MRIs at a fraction of the cost, Swoop captures images in minutes, providing critical decision-making capabilities in emergency departments, operating rooms outside the sterile field, and intensive care units, among others. Hyperfine was founded in 2014 by Jonathan Rothberg, Ph.D., a serial entrepreneur and the founder or co-founder of numerous other innovative companies, including CuraGen, 454 Life Sciences, Ion Torrent, RainDance Technologies, ClariFI, Quantum-Si, AI Therapeutics, Butterfly Network, 4Catalyzer, and 4Bionics. In 2015, Rothberg was awarded the National Medal of Technology and Innovation by President Obama for inventing and commercializing DNA sequencing. For more information visit www.hyperfine.io.
Forward-Looking Statements
This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Hyperfine’s actual results may differ from its expectations, estimates and projections and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, expectations about Hyperfine’s financial and operating results, the benefits of Hyperfine’s products and services, and Hyperfine’s future performance and its ability to implement its strategy. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Most of these factors are outside of Hyperfine’s control and are difficult to predict. Factors that may cause such differences include, but are not limited to: the success, cost and timing of Hyperfine product development and commercialization activities, including the degree that Swoop is accepted and used by healthcare professionals; the impact of COVID-19 on Hyperfine’s business; the inability to maintain the listing of Hyperfine’s Class A common stock on the Nasdaq; the inability to recognize the anticipated benefits of the business combination, which may be affected by, among other things, competition and Hyperfine’s ability to grow and manage growth profitably and retain its key employees; changes in applicable laws or regulations; the inability of Hyperfine to raise financing in the future; the inability of Hyperfine to obtain and maintain regulatory clearance or approval for its products, and any related restrictions and limitations of any cleared or approved product; the inability of Hyperfine to identify, in-license or acquire additional technology; the inability of Hyperfine to maintain its existing or future license, manufacturing, supply and distribution agreements and to obtain adequate supply of its products; the inability of Hyperfine to compete with other companies currently marketing or engaged in the development of products and services that Hyperfine is currently marketing or developing; the size and growth potential of the markets for Hyperfine’s products and services, and its ability to serve those markets, either alone or in partnership with others; the pricing of Hyperfine’s products and services and reimbursement for medical procedures conducted using Hyperfine’s products and services; Hyperfine’s estimates regarding expenses, future revenue, capital requirements and needs for additional financing; Hyperfine’s financial performance; and other risks and uncertainties indicated from time to time in Hyperfine’s filings with the Securities and Exchange Commission, including those under “Risk Factors” therein. Hyperfine cautions readers that the foregoing list of factors is not exclusive and that readers should not place undue reliance upon any forward-looking statements, which speak only as of the date made. Hyperfine does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based.
Investor Contact |
Marissa Bych |
Gilmartin Group LLC |
marissa@gilmartinir.com |